Küldje el az oldalt ismerősének!
google +
Nyomtatóbarát változat

Hírek (Ritka betegségek)

This section on health in the EU has been created as a trustworthy gateway to a wide range of information and data on health-related issues and activities at both European, national and international level. The content is produced by the European Commission, the Member States of the EU and the European Economic Area (EEA), plus EU candidate countries; by international organisations; and by pan-European non-governmental organisations in the area of public health.

Registration opens for workshop on clinical trial design in neuromyelitis optica to facilitate global medicine development in a rare and serious disease    europa.eu

Registration is now open for a regulatory workshop on clinical trial design in neuromyelitis optica and spectrum disorders at the European Medicines Agency on 10 October 2014.[...]

New resource for educators: Discussion games: Orphan drugs    xplorehealth.eu

Game to engage in a dialogue | How are drugs developed? Orphan drugs are medicines which have been developed to diagnose and treat rare diseases. Although they can be beneficial for millions of peop[...]

Events - International Rare Disease Research Consortium Shenzhen Conference - 7-9 November 2014, Shenzhen, China    europa.eu

The second conference organized by IRDiRC in collaboration with the BGI is gathering stakeholders active in the field of rare disease from across the globe. This conference aims to raise awareness of[...]

European Medicines Agency and US Food and Drug Administration release joint proposal to facilitate clinical investigation of new medicines for Gaucher disease in children    europa.eu

The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) have released today a draft joint proposal to facilitate the clinical investigation of new medicines for t[...]

Test your knowledge with the new ECG quiz    escardio.org

An 18-year-old female attends a routine occupational medical in order to join the British Army. She represents her school and region in cross-country running and hockey. She is asymptomatic with no f[...]

European Medicines Agency recommends approval of a locally targeted treatment for ulcerative colitis and Crohn’s disease    europa.eu

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Entyvio (vedolizumab) for the treatment of adult patients [...]

Joint EMA/FDA/MHLW-PMDA orphan medicinal product workshop takes place today    europa.eu

A workshop on orphan product designation and grants is taking place today at the European Medicines Agency (EMA), jointly organised by the EMA, the US Food and Drug Administration (FDA) and for the f[...]

Safe treatment for AK, a rare eye disease    europa.eu

The ODAK ('Orphan Drug for Acanthamoeba Keratitis') project is working to develop a safe and effective treatment for Acanthamoeba keratitis (AK), a rare infectious eye disease which causes severe deb[...]

Health-EU Newsletter: Rare Disease Day 2014: Joining together across Europe for better care    europa.eu

We are breaking the isolation and despair of children and adults who are amongst the most vulnerable citizens in our society today. By bringing together all 6000 different rare diseases across Europ[...]

Towards establishing a European platform on rare diseases registration    europa.eu

Rare Disease Day is observed internationally on the last day of February. Its global objective is to raise awareness for rare diseases and improve access to treatment and medical representation for i[...]

European Rare Diseases Day: Top facts on EU Action    europa.eu

European Commission - Press Release details page - Commission MEMO Brussels, 27 February 2014 European A disease or disorder is defined as rare in the EU when it affects less than five in every 10 0[...]

Rare Disease Day 2014 – twelve new orphan medicines available to patients over the past year    europa.eu

Over the past twelve months, a total of 12 medicines for the treatment of rare diseases were recommended for marketing authorisation by the European Medicines Agency's (EMA) Committee for Medicinal P[...]


The European Commission is solely responsible for information present on EU-level websites, information present in the Portal originated by the Commission. National-level information is provided by the Member States concerned and Member States are solely responsible for the accuracy of the information. Likewise, the European Commission is not responsible for information on non-governmental organisations and international organisations websites. The European Union is committed to user privacy. Read more concerning the Legal Notice.
Further questions can be answered through the Contact page. The Health-EU portal supports principles and measures to increase the credibility of information on the net. It complies with the HONcode standard for trustworthy health information: verify here.